Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 147

Similar articles for PubMed (Select 21850687)

1.

Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death.

Angeles DC, Gan BH, Onstead L, Zhao Y, Lim KL, Dachsel J, Melrose H, Farrer M, Wszolek ZK, Dickson DW, Tan EK.

Hum Mutat. 2011 Dec;32(12):1390-7. doi: 10.1002/humu.21582. Epub 2011 Sep 12.

PMID:
21850687
2.

LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity.

Heo HY, Park JM, Kim CH, Han BS, Kim KS, Seol W.

Exp Cell Res. 2010 Feb 15;316(4):649-56. doi: 10.1016/j.yexcr.2009.09.014. Epub 2009 Sep 19.

PMID:
19769964
3.

Thiol peroxidases ameliorate LRRK2 mutant-induced mitochondrial and dopaminergic neuronal degeneration in Drosophila.

Angeles DC, Ho P, Chua LL, Wang C, Yap YW, Ng C, Zhou Zd, Lim KL, Wszolek ZK, Wang HY, Tan EK.

Hum Mol Genet. 2014 Jun 15;23(12):3157-65. doi: 10.1093/hmg/ddu026. Epub 2014 Jan 23.

PMID:
24459295
4.

Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein.

Niu J, Yu M, Wang C, Xu Z.

J Neurochem. 2012 Aug;122(3):650-8. doi: 10.1111/j.1471-4159.2012.07809.x. Epub 2012 Jun 22.

PMID:
22639965
5.

Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.

Lu YW, Tan EK.

J Neurosci Res. 2008 Jul;86(9):1895-901. doi: 10.1002/jnr.21656. Review.

PMID:
18338801
6.

Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation.

Luzón-Toro B, Rubio de la Torre E, Delgado A, Pérez-Tur J, Hilfiker S.

Hum Mol Genet. 2007 Sep 1;16(17):2031-9. Epub 2007 Jun 20.

7.

GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.

Stafa K, Trancikova A, Webber PJ, Glauser L, West AB, Moore DJ.

PLoS Genet. 2012;8(2):e1002526. doi: 10.1371/journal.pgen.1002526. Epub 2012 Feb 9.

8.

The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.

Rudenko IN, Kaganovich A, Hauser DN, Beylina A, Chia R, Ding J, Maric D, Jaffe H, Cookson MR.

Biochem J. 2012 Aug 15;446(1):99-111. doi: 10.1042/BJ20120637.

9.

LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1.

Wang X, Yan MH, Fujioka H, Liu J, Wilson-Delfosse A, Chen SG, Perry G, Casadesus G, Zhu X.

Hum Mol Genet. 2012 May 1;21(9):1931-44. doi: 10.1093/hmg/dds003. Epub 2012 Jan 6.

10.

A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.

Illarioshkin SN, Shadrina MI, Slominsky PA, Bespalova EV, Zagorovskaya TB, Bagyeva GKh, Markova ED, Limborska SA, Ivanova-Smolenskaya IA.

Eur J Neurol. 2007 Apr;14(4):413-7.

PMID:
17388990
11.

LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study.

Sharma S, Bandopadhyay R, Lashley T, Renton AE, Kingsbury AE, Kumaran R, Kallis C, Vilariño-Güell C, O'Sullivan SS, Lees AJ, Revesz T, Wood NW, Holton JL.

Neuropathol Appl Neurobiol. 2011 Dec;37(7):777-90. doi: 10.1111/j.1365-2990.2011.01187.x.

PMID:
21696411
12.

G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization.

Papkovskaia TD, Chau KY, Inesta-Vaquera F, Papkovsky DB, Healy DG, Nishio K, Staddon J, Duchen MR, Hardy J, Schapira AH, Cooper JM.

Hum Mol Genet. 2012 Oct 1;21(19):4201-13. doi: 10.1093/hmg/dds244. Epub 2012 Jun 26.

13.

Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration?

Gillardon F.

J Neurochem. 2009 Sep;110(5):1514-22. doi: 10.1111/j.1471-4159.2009.06235.x. Epub 2009 Jun 22.

PMID:
19545277
14.

Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation.

Su YC, Qi X.

Hum Mol Genet. 2013 Nov 15;22(22):4545-61. doi: 10.1093/hmg/ddt301. Epub 2013 Jun 27.

15.

A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2.

Dusonchet J, Kochubey O, Stafa K, Young SM Jr, Zufferey R, Moore DJ, Schneider BL, Aebischer P.

J Neurosci. 2011 Jan 19;31(3):907-12. doi: 10.1523/JNEUROSCI.5092-10.2011.

16.

Apoptotic mechanisms in mutant LRRK2-mediated cell death.

Iaccarino C, Crosio C, Vitale C, Sanna G, Carrì MT, Barone P.

Hum Mol Genet. 2007 Jun 1;16(11):1319-26. Epub 2007 Apr 4.

17.

LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans.

Lesage S, Janin S, Lohmann E, Leutenegger AL, Leclere L, Viallet F, Pollak P, Durif F, Thobois S, Layet V, Vidailhet M, Agid Y, Dürr A, Brice A; French Parkinson's Disease Genetics Study Group, Bonnet AM, Borg M, Broussolle E, Damier P, Destée A, Martinez M, Penet C, Rasco O, Tison F, Tranchan C, Vérin M.

Arch Neurol. 2007 Mar;64(3):425-30.

PMID:
17353388
18.

Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications.

Qing H, Wong W, McGeer EG, McGeer PL.

Biochem Biophys Res Commun. 2009 Sep 11;387(1):149-52. doi: 10.1016/j.bbrc.2009.06.142. Epub 2009 Jul 1.

PMID:
19576176
19.

The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity.

Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, Meitinger T, Kolch W, Prokisch H, Ueffing M.

Hum Mol Genet. 2006 Jan 15;15(2):223-32. Epub 2005 Dec 1.

20.

The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Thaler A, Ash E, Gan-Or Z, Orr-Urtreger A, Giladi N.

J Neural Transm. 2009 Nov;116(11):1473-82. doi: 10.1007/s00702-009-0303-0. Review.

PMID:
19756366
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk